Adalvo is thrilled to announce the successful launch of Desmopressin in multiple countries across Europe, in collaboration with key strategic partners.
Developed based on the reference brand Minirin Melt from Ferring, Desmopressin is indicated for treating diabetes insipidus, primary nocturnal enuresis, and nocturia. With global sales reaching $168 million in 2023, according to IQVIA, these launches mark a significant addition to Adalvo's pharmaceutical portfolio.
By collaborating with strategic partners, Adalvo aims to deliver high-quality and innovative pharmaceutical solutions to improve patient outcomes.
"Our collaborative effort with strategic partners reflects Adalvo's dedication to excellence in the pharmaceutical industry," said Anil Okay, CEO of Adalvo. "We are excited about the successful introduction of Desmopressin in multiple countries and remain committed to expanding our presence to impact patient care worldwide positively."
At Adalvo, there are no half-measures - we are always on target. When your mission is to surpass your competitors, you need a dedicated team driving your vision forward.
Partner with us now!